今天给大家谈谈度那雄胺这个药

Currently, the treatment methods for benign prostatic hyperplasia (BPH) mainly include drug therapy and surgical treatment. For patients with benign prostatic hyperplasia who do not require surgery, multinational guidelines recommend the use of 5α-reductase inhibitors, α-receptor blockers, or a combination of the two. There are currently two types of 5α-reductase inhibitors, finasteride and dunasteride. Finasteride is a traditional 5α-reductase inhibitor that has been on the market for 28 years. It was approved by the US FDA and launched in the fall of 2004. It is used to treat symptomatic prostatic hyperplasia in men with prostatic hypertrophy to improve urinary symptoms, reduce the risk of acute urinary retention, and reduce the need for surgical intervention related to prostatic hyperplasia. Today I’m going to talk to you about the drug Dunasteride.

Dunasteride is a second-generation agent. Compared with traditional fitaxionate, it has a more obvious inhibitory effect on patients' serum DHT. It has a significant effect in reducing prostate volume, improving maximum urine flow, reducing IPSS and QOL scores, and reducing PSA levels.

Dunasteride can dually block type Ⅰ and type Ⅱ 5α reductase. Theoretically, it has a faster onset of action and more significant effect than finasteride, and is more advantageous in reducing bleeding during TURP surgery. However, there is currently a lot of controversy about the course of dunasteride application before TURP. MIT-TERBERGER et al. found through color Doppler that intraprostatic blood flow was significantly reduced after taking dunasteride for 1 week. PASTORE et al. pointed out in the report that taking dunasteride for 6 weeks before TURP can effectively reduce surgical bleeding.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.